Peptide LibraryResearch statistics
Dasiglucagon research: publications and trials
At a glance
Publications, all years
43
Since 2017
Publications in 2026 so far
1
Through November 1, 2026
Human clinical research
38.1%
16 of 42 classified
Registered clinical trials
24
ClinicalTrials.gov
Randomized controlled trials
14
Publications reporting an RCT in people
Systematic reviews and meta-analyses
3
Preclinical studies
9.5%
2 animal · 1 in vitro · 1 computational
Records that only mention it
5
Not counted above
Status in the library: FDA-approved. 1 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Dasiglucagon publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2017 | 1 | 0 | 0 | 0 | 1 |
| 2018 | 1 | 1 | 0 | 0 | 2 |
| 2019 | 0 | 0 | 1 | 1 | 2 |
| 2020 | 0 | 0 | 1 | 0 | 1 |
| 2021 | 5 | 0 | 5 | 2 | 12 |
| 2022 | 3 | 1 | 3 | 0 | 7 |
| 2023 | 3 | 0 | 5 | 0 | 8 |
| 2024 | 1 | 1 | 1 | 2 | 5 |
| 2025 | 2 | 0 | 0 | 2 | 4 |
| 2026 (to date) | 0 | 1 | 0 | 0 | 1 |
Study types
| Randomized controlled trial | 14 |
|---|---|
| Review | 13 |
| Editorial, letter or other | 6 |
| Meta-analysis | 3 |
| Animal study | 2 |
| Case report | 2 |
| Computational study | 1 |
| In vitro study | 1 |
| Not yet classified | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 39 |
|---|---|
| Endocrinology | 25 |
| Immune system | 18 |
| Gastrointestinal | 4 |
| Cardiovascular | 1 |
| Cognitive health | 1 |
| Dermatology | 1 |
| Neurological and mental health | 1 |
Registered clinical trials
7 of 21 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 21 · Withdrawn: 3
Early phase 1: 1 · Phase 1: 4 · Phase 2: 9 · Phase 2 / Phase 3: 2 · Phase 3: 8
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis
Balkan medical journal · September 22, 2023 · Meta-analysis · cited 1 times · open access
PMID 37735694 · DOI 10.4274/balkanmedj.galenos.2023.2023-7-84 · Reviews and meta-analyses
- Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.
Diabetes, obesity & metabolism · February 14, 2023 · Meta-analysis · cited 1 times · open access
PMID 36692230 · DOI 10.1111/dom.14987 · Reviews and meta-analyses
- Clinical efficacy and safety of dasiglucagon in severe hypoglycemia associated with patients of type 1 diabetes mellitus: a systematic review and meta-analysis.
Expert review of clinical pharmacology · October 25, 2022 · Meta-analysis · cited 2 times
PMID 36266088 · DOI 10.1080/17512433.2023.2138343 · Reviews and meta-analyses
- Dasiglucagon in Children With Congenital Hyperinsulinism Up to 1 Year of Age: Results From a Randomized Clinical Trial.
The Journal of clinical endocrinology and metabolism · July 1, 2025 · Randomized controlled trial · cited 5 times · open access
PMID 39584500 · DOI 10.1210/clinem/dgae818 · Human clinical research
- Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children.
The Journal of clinical endocrinology and metabolism · March 1, 2024 · Randomized controlled trial · cited 14 times · open access
PMID 37930757 · DOI 10.1210/clinem/dgad648 · Human clinical research
- Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial.
Diabetes care · December 1, 2023 · Randomized controlled trial · cited 15 times · open access
PMID 37819999 · DOI 10.2337/dc23-1193 · Human clinical research
- Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial.
Diabetologia · April 11, 2023 · Randomized controlled trial · cited 6 times · open access
PMID 37037948 · DOI 10.1007/s00125-023-05909-4 · Human clinical research
- Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.
Diabetes care · June 1, 2022 · Randomized controlled trial · cited 10 times · open access
PMID 35475907 · DOI 10.2337/dc21-2304 · Human clinical research
- Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
Diabetes care · June 1, 2022 · Randomized controlled trial · cited 17 times
PMID 35320361 · DOI 10.2337/dc21-2252 · Human clinical research
- Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study.
Current therapeutic research, clinical and experimental · March 29, 2022 · Randomized controlled trial · cited 2 times · open access
PMID 35464292 · DOI 10.1016/j.curtheres.2022.100668 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
Diabetes care · December 22, 2017 · Randomized controlled trial · cited 115 times
PMID 29273578 · DOI 10.2337/dc17-1402 · Human clinical research
- Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting.
Diabetes care · April 27, 2021 · Editorial, letter or other · cited 75 times · open access
PMID 33906916 · DOI 10.2337/dc20-1086 · Commentary and other
- Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
Diabetes care · June 1, 2021 · Randomized controlled trial · cited 54 times · open access
PMID 35239971 · DOI 10.2337/dc20-2995 · Human clinical research
- Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia.
Current diabetes reports · September 6, 2019 · Review · cited 46 times · open access
PMID 31493043 · DOI 10.1007/s11892-019-1216-4 · Reviews and meta-analyses
- Glucose-Driven Droplet Formation in Complexes of a Supramolecular Peptide and Therapeutic Protein.
Journal of the American Chemical Society · March 11, 2024 · Animal study · cited 44 times
PMID 38465595 · DOI 10.1021/jacs.3c13139 · Animal studies
Latest publications
- Engineering a Glucose-Responsive Glucagon Prodrug Through Arginine-Phenylboronic Acid Pendant Modification.
Small science · March 6, 2026 · Animal study · cited 2 times · open access
PMID 41810046 · DOI 10.1002/smsc.202500555 · Animal studies
- Dasiglucagon in Children With Congenital Hyperinsulinism Up to 1 Year of Age: Results From a Randomized Clinical Trial.
The Journal of clinical endocrinology and metabolism · July 1, 2025 · Randomized controlled trial · cited 5 times · open access
PMID 39584500 · DOI 10.1210/clinem/dgae818 · Human clinical research
- Necrolytic migratory erythema following prolonged continuous subcutaneous dasiglucagon administration: a rare dermatologic adverse event.
Endocrinology, diabetes & metabolism case reports · April 29, 2025 · Case report · cited 3 times · open access
PMID 40300042 · DOI 10.1530/edm-25-0006 · Human clinical research
- Letter to the Editor From He et al: "Dasiglucagon in Children With Congenital Hyperinsulinism up to 1 Year of Age: Results From a Randomized Clinical Trial".
The Journal of clinical endocrinology and metabolism · April 1, 2025 · Editorial, letter or other · cited 1 times
PMID 39985816 · DOI 10.1210/clinem/dgaf101 · Commentary and other
- Response to Letter to the Editor From He et al: "Dasiglucagon in Children With Congenital Hyperinsulinism up to 1 Year of Age: Results From a Randomized Clinical Trial".
The Journal of clinical endocrinology and metabolism · April 1, 2025 · Editorial, letter or other · cited 1 times · open access
PMID 39985817 · DOI 10.1210/clinem/dgaf102 · Commentary and other
- Dasiglucagon: a New Hope for Managing Post-prandial Hypoglycemia After Gastric Bypass Surgery?
Obesity surgery · November 1, 2024 · Editorial, letter or other · cited 0 times
PMID 39482446 · DOI 10.1007/s11695-024-07574-x · Commentary and other
- Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon.
Cellular and molecular neurobiology · July 8, 2024 · Review · cited 12 times · open access
PMID 38977507 · DOI 10.1007/s10571-024-01489-y · Reviews and meta-analyses
- Dasiglucagon: A New Hope for Diazoxide-unresponsive, Nonfocal Congenital Hyperinsulinism?
The Journal of clinical endocrinology and metabolism · June 1, 2024 · Editorial, letter or other · cited 2 times · open access
PMID 38104245 · DOI 10.1210/clinem/dgad741 · Commentary and other
- Glucose-Driven Droplet Formation in Complexes of a Supramolecular Peptide and Therapeutic Protein.
Journal of the American Chemical Society · March 11, 2024 · Animal study · cited 44 times
PMID 38465595 · DOI 10.1021/jacs.3c13139 · Animal studies
- Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children.
The Journal of clinical endocrinology and metabolism · March 1, 2024 · Randomized controlled trial · cited 14 times · open access
PMID 37930757 · DOI 10.1210/clinem/dgad648 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Dasiglucagon; Zegalogue; ZP4207; ZP-GA-1
((TITLE_ABS:"Dasiglucagon" OR CHEM:"Dasiglucagon") OR (TITLE_ABS:"Zegalogue" OR CHEM:"Zegalogue") OR (TITLE_ABS:"ZP4207" OR CHEM:"ZP4207" OR TITLE_ABS:"ZP 4207" OR CHEM:"ZP 4207") OR (TITLE_ABS:"ZP-GA-1" OR CHEM:"ZP-GA-1" OR TITLE_ABS:"ZP-GA1" OR CHEM:"ZP-GA1")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Dasiglucagon research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/dasiglucagon